ERBB2 and breast cancer: In 2022, Davey MG and associates published a systematic review in Breast Cancer (Auckl) regarding the involvement of miRNA in forecasting responses to neoadjuvant therapy in HER2/neu-enriched molecular subtype breast cancer [83].